PharmaEngine announced that the China NMPA has granted approval for ONIVYDE Regimen for the Treatment of Metastatic Pancreatic Cancer
· Issued by PharmaEngine, Inc.
Close
Today's Information
Provided by: PharmaEngine, Inc.
SEQ_NO
2
Date of announcement
2022/04/15
Time of announcement
15:12:24
Subject
PharmaEngine Inc. announced that the China NMPA
has granted approval for ONIVYDE Regimen for the
Treatment of Metastatic Pancreatic Cancer
Date of events
2022/04/15
To which item it meets
paragraph 53
Statement
1.Date of occurrence of the event:2022/04/15
2.Company name:PharmaEngine Inc.
3.Relationship to the Company (please enter "head office" or
"subsidiaries"):Head office
4.Reciprocal shareholding ratios:NA
5.Cause of occurrence:ONIVYDE in combination with fluorouracil (5-FU) and
leucovorin (LV) has been approved by China National Medical Products
Administration (NMPA) for the treatment of patients with metastatic
pancreatic cancer after disease progression following gemcitabine-based
therapy.
6.Countermeasures:NA
7.Any other matters that need to be specified:According to the WHO estimates
124,994 new cases of pancreatic cancer were registered China in 2020.
Pancreatic cancer has ranked as the 8th most common cancer in China.
